On 20 July 2026, Samsung Biologics announced that it has entered into an all-cash public tender to acquire 100% of PolyPeptide Group AG, a leading Swiss-based global contract development and manufacturing organisation (CDMO), specialised in peptide-based active pharmaceutical ingredients.
Under the terms of the tender offer, PolyPeptide Group shareholders will receive CHF 44.31 in cash per share. The transaction is expected to close at the end of 2026, subject to regulatory approvals and closing conditions.
This acquisition will allow Samsung Biologics to leverage PolyPeptide Group’s peptide-based capabilities and expand its current CDMO offerings beyond antibodies and ADCs, addressing growing demand for peptide-based therapeutics, particularly in obesity and diabetes, including GLP-1 therapies.
Following the November 2025 spin-off of biosimilar operations into a new holding entity, Samsung Epis Holdings, Samsung Biologics has focused on its contract development and manufacturing business.